Real questions from health communities, answered with cited research from PubMed and Vellito's article corpus. Plain language, no medical advice. How this works.
ATRA plus ATO for APL achieves 3-year overall survival of 95% and 10-year survival of ≥80%, with complete remission rates over 95%.
Becotatug vedotin showed a 20.9% objective response rate in recurrent or metastatic head and neck squamous cell carcinoma after prior therapy.
Yes, different receptor types in metastatic breast cancer lesions are linked to different survival times, with hormone receptor-positive subtypes generally having longer survival…
Receptor discordance in metastatic breast cancer is linked to worse overall survival, especially when hormone receptors are lost.
Yes, hospital-acquired infections significantly increase medical costs for discharged cancer center patients, including higher hospitalization costs and greater deficits under…
CAR-T therapy for B-cell malignancies has transformed treatment but carries risks like B-cell aplasia and cytokine release syndrome. New approaches aim to improve safety while…
Reviews indicate that while CAR-T therapy is established for B-cell malignancies, there are currently no specific outcomes or safety data available for its use in pancreatic…
Morning timing of immune checkpoint infusions is linked to better survival in metastatic non-small cell lung cancer, while other new drugs like magrolimab have not shown clear…
Cancer research is producing new treatments for autoimmune diseases by adapting cell therapies like CAR-T cells and targeting shared inflammatory pathways such as IRAK4 and…
In rare cancers treated with nivolumab plus ipilimumab, having a larger tumor burden at the start of treatment is linked to shorter overall survival.
A nurse-led music intervention shows early promise for reducing feelings of cognitive impairment in colorectal cancer patients, though it is not yet proven for all cancer types.
Lifileucel is a cell therapy that uses your own immune cells to fight metastatic melanoma after other treatments fail. It involves removing tumor cells, growing immune cells in a…
Research shows that targeting shared molecular pathways like Siglec signaling, mitochondrial cell death, and immune metabolism offers new ways to treat both autoimmune disorders…
Siglec signaling pathways are linked to autoimmune and inflammatory disorders, neurodegeneration, and infections in addition to cancer.
Adjuvant chemotherapy regimens for early-stage breast cancer have distinct safety profiles; TAC causes more febrile neutropenia, while AC→T leads to more neuropathy and hand-foot…
Activity pacing interventions show a small but not statistically significant effect on cancer-related fatigue overall, but may significantly help patients undergoing chemotherapy.
Yes, acupuncture appears to significantly improve cancer-related fatigue, with recent meta-analyses showing moderate benefit, though study quality is limited.
PROTACs are not yet available as approved treatments for most oncology conditions, though one specific drug, vepdegestrant, is in clinical trials for advanced breast cancer.
Yes, radical perineal prostatectomy typically causes less blood loss than the retropubic approach for localized prostate cancer, based on direct comparative studies.
Artificial intelligence helps kidney cancer patients by improving tumor detection on scans, planning robotic surgeries, and predicting surgical outcomes to reduce complications.
Yes, the 2025 EAU guidelines update kidney cancer care with new recommendations on stereotactic body radiotherapy, adjuvant therapy, and systemic treatments for clear-cell and…
In nonsquamous advanced NSCLC, camrelizumab was linked to a higher risk of disease progression and death than pembrolizumab in second-line or later treatment, based on one…
For advanced NSCLC, immunotherapy (especially pembrolizumab) is highly effective for high PD-L1 tumors, while chemotherapy remains a backbone; combining both may improve outcomes.
Yes, real-world data from over 17,500 patients shows pembrolizumab is effective as first-line treatment for advanced NSCLC with high PD-L1 (≥50%), with median overall survival of…
We pull real patient questions from public Reddit health communities (r/AskDocs, r/diabetes, r/menopause, etc.). Each question is rewritten into a generic medical question (no personal details), then answered by an AI using only cited sources from Vellito's article database and PubMed. A second AI independently scores each answer for accuracy and citation fidelity before publication. Answers below the safety threshold or touching emergency, dosing, or pediatric topics are queued for human review and never auto-published.
This is not medical advice. Always speak with your own doctor before making decisions about your health.